News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wasatch Advisors LP significantly increased its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 125.8% in the second quarter, now owning 115,668 shares valued at $11.5 million. This comes as other institutional investors also adjusted their positions in the medical instruments supplier. Despite an overall …
Mesa Laboratories' stock jumped 9.5% after its Q1 2027 earnings, with investors focusing on improved profitability despite modest revenue growth. Gross margins increased, and cash generation was solid, but net income and EPS declined year-on-year. The company faces risks from backlog issues and customer …
Mesa Laboratories reported a 1% increase in Q1 revenue to $60.1 million, with adjusted operating income surging nearly 20% and gross margin expanding to 64.9% due to cost controls. The company generated $14.7 million in operating cash flow and repaid $8.7 million in debt, …
This is a press release from Mesa Labs announcing their first-quarter results. The document provided was empty, so no further summary can be generated.
Mesa Laboratories Inc. (MLAB) reported its Q1 2027 earnings, showing a 1% increase in total revenue to $60.1 million and a significant 16.5% rise in adjusted operating income. The company achieved margin expansion and reduced its net leverage ratio to 1.85x by repaying $8.7 …
Earnings Call Insights: Mesa Laboratories (MLAB) Q1 2027 MANAGEMENT VIEW * CEO Siddhartha Kadia framed his first call around execution fixes and capital allocation, saying, "Mesa is a set of durable, regulation embedded franchises with real and growing earnings power that had fixable execution …
Mesa Laboratories Inc /Co/ reported its 2026 quarterly results with revenue slightly up to $60.14M from $59.54M the previous year. However, net income decreased by 40.3% to $2.83M, and diluted EPS fell by 42.4% to $0.49. The company highlighted revenue growth in Calibration Solutions …
Mesa Laboratories (MLAB) reported Q1 FY2027 revenue of $60,138, a 1.0% increase year-over-year, with gross profit rising to $39,012 due to improved gross margins. Operating income more than doubled to $7,031, and operating cash flow strengthened significantly to $14,736, leading to a net debt …
Mesa Laboratories, Inc. announced its first fiscal quarter results, showing a 1.0% increase in revenues and a 129% increase in operating income. The company reported positive core organic growth driven by its Calibration Solutions and Biopharmaceutical Development divisions, with a significant reduction in its …
Renaissance Technologies LLC significantly increased its stake in Mesa Laboratories (MLAB) by 802.9% in Q1, now holding 31,600 shares valued at $2.79 million. Despite institutional ownership reaching 90.6%, the company missed Q1 analyst estimates for revenue and EPS. Analysts maintain a "Reduce" rating for …
Mesa Laboratories Inc (MLAB) has an earnings forecast score of 7.33, ranking 141st in its industry, with an average price target of $95.00 from three analysts. Analysts generally recommend a "Buy" for MLAB, anticipating next quarter's revenue at $60.87 million and EPS at $0.03.
Mesa Laboratories, Inc. (MLAB) is anticipated to report earnings of 3 cents per share. This earnings preview is based on information from Refinitiv and was published on TradingView News.
Janus Henderson Group PLC significantly reduced its stake in Mesa Laboratories, Inc. by 40.5% in the first quarter of 2026, selling over 47,000 shares. Despite other institutional investors increasing their holdings, company insiders sold a substantial number of shares. Mesa Laboratories also missed its …
Lazard Asset Management LLC has acquired a new stake of 20,328 shares in Mesa Laboratories (MLAB), valued at approximately $1.8 million, bringing institutional ownership to 90.6% of the company. Despite missing analyst estimates for quarterly revenue and earnings, the stock recently rose by 3.6% …
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its first fiscal quarter (1Q27) financial results, ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its first earnings conference call on the same day at 4:30 p.m. …
Mesa Labs (MSLB) will release its financial results for the first quarter of fiscal 2027, ending June 30, 2026, on August 10 after market close. The company will also host an earnings conference call at 4:30 p.m. Eastern Time on the same day to …
Mesa Labs (NASDAQ: MLAB) announced it will release its first fiscal quarter (1Q27) financial results, for the period ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its inaugural earnings conference call on the same day …
This article provides a technical analysis of Mesa Laboratories Inc (MLAB), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 29, 2026, MLAB's price momentum score is 3.97, suggesting it is suitable for range-bound swing trading between …
Mesa Laboratories Inc (MLAB) currently holds a financial score of 7.93, ranking 56th in the Healthcare Equipment & Supplies industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $63.72M, marking a 2.56% year-over-year increase, and a …
This report provides a comprehensive stock analysis of Mesa Laboratories (MLAB), detailing its company overview, valuation metrics, future growth potential, past performance, financial health, dividend information, management, and ownership. Key highlights include its current trading value below fair value estimates, projected earnings growth of …
This article details the historical dividend payouts for Mesa Laboratories Inc (MLAB), showing a consistent interim and final cash dividend of $0.16 per share. It lists future dividend dates including record, payment, and ex-dividend dates extending into 2026. The company has distributed a total …
Mesa Laboratories Inc. (MLAB) closed at $97.50, down 3.42%, with a market cap of $538.68M. Analysts rate MLAB as "Buy" with a target price of $112.00, representing a 14.86% upside. The company shows strong fundamentals with steady revenue growth and a return to profitability, …
Mesa Laboratories Inc (MLAB) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding increased by 17.49% quarter-over-quarter, with Chuck Royce being the largest shareholder. The article details major institutional holders and their recent changes …
Mesa Laboratories Inc (MLAB) has a current valuation score of 9.21, ranking 34th out of 200 in its industry. Its P/E ratio is 148.35, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not …
Search by ticker symbol or company name and select a result to open its chart.